NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) — Alpex Acquisition Corporation (NASDAQ: ALPXU) (“Alpex”) announced the pricing of its initial public offering (the “IPO”) of 10,000,000 units at $10.00 per unit. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under “ALPXU” beginning June 25, 2026. Each unit consists of one Class A ordinary share, one redeemable warrant, and one right to receive one-fourth of one Class A ordinary share upon consummation of an initial business combination. Each whole redeemable warrant entitles the holder thereof to purchase one Class A ordinary share at an exercise price of $11.50 per share. Upon separate trading, the Class A ordinary shares, warrants and rights are expected to be listed on Nasdaq under “ALPX,” “ALPXW,” and “ALPXR,” respectively. D. Boral...

PERTH, Australia, June 24, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) announces it has successfully completed its 2026 winter drilling program at the Patterson Lake South (PLS) high-grade uranium project, located in the Athabasca Basin region of Saskatchewan, Canada, with the discovery of a new body of high-grade uranium mineralisation, the Atlas discovery.  HighlightsHigh-grade uranium mineralisation has been intersected 3.5km south of Paladin’s Triple R deposit and 4.5km southwest of Saloon East. Eight (8) exploration drillholes were collared, with seven intersecting significant uranium mineralisation at the new Atlas discovery, totalling 2,408m. Key winter 2026 intercepts at Atlas include:PLS26-708B (discovery drillhole): 17.5m of total composite uranium mineralisation...

Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. Mesoblast had US$122 million cash at March 30, 2026. In aggregate Mesoblast is well funded to invest in its commercial operations and growth pipeline, and optimize its capital structure by retiring the higher cost NovaQuest Capital Management LLC debt facility eliminating the short-term debt obligations. The credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from prior facilities,...

New York, N.Y., June 24, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, today announced recent and upcoming high-profile engagements with government officials, industry leaders, multilateral organizations, and energy stakeholders across Asia, Africa, Latin America, and the Caribbean as well as a management team update. Global Strategic Engagements Across Emerging Nuclear Markets As part of NANO Nuclear’s efforts to build key relationships, knowledge base, and market presence necessary to support future reactor deployment opportunities across emerging global nuclear markets, NANO Nuclear has actively participated in international forums focused on advancing nuclear...

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements — HONG KONG and FLORHAM PARK, N.J., June 25, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress taking place from July 1 to 4, 2026 in Munich, Germany. Supported by data from the study, a New Drug Application (NDA) for fanregratinib for the treatment of adult patients with advanced,...

VANCOUVER, British Columbia, June 24, 2026 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V: WHN) (OTCQB: WTHVF) (“Westhaven” or the “Company”) is pleased to announce the voting results from the Company’s Annual General Meeting of Shareholders held on June 24, 2026. Shareholders approved all motions put forth at the meeting including the re-appointment of Smythe LLP, Chartered Professional Accountants, as the Company’s independent auditors, and the Company’s 2026 Equity Incentive Plan. The shareholders elected Hannah McDonald, Paul McRae, Victor Tanaka, Eira Thomas, Gareth Thomas, Patrick Anderson and Kenneth Armstrong to the Company’s Board of Directors. A total of 98,153,013 common shares were voted, representing the votes attached to 37.73% of all outstanding common shares. The votes cast were as follows:Resolution For...

VANCOUVER, British Columbia, June 24, 2026 (GLOBE NEWSWIRE) — SNOWLINE GOLD CORP. (TSX: SGD) (OTCQB: SNWGF) (the “Company” or “Snowline”) is pleased to announce the results of voting at its Annual General and Special Meeting of Shareholders (“Meeting”) held on June 24, 2026, in Whitehorse, YT. A total of 114,557,973 common shares of the Company were voted, representing approximately 65.13% of total shares issued and outstanding as at the record date of the Meeting. Shareholders voted in favour of all items put forward by the Company, including approval of the amended and restated omnibus incentive plan, and re-appointment of Crowe Mackay LLP as auditor of the Company. At the Meeting, the number of directors was set at seven and all director nominees listed in the Company’s management information circular dated May 11, 2026,...